Title: The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review Frezza EE, Wachtel MS, Chiriva-Internati M Ref: Digestive Diseases & Sciences, 52:643, 2007 : PubMed
By itself, glucagon-like peptide-1(GLP-1) appears to be an excellent drug for appetite control and the treatment of obesity. Unfortunately, few enzymes, such as IV dipeptidyl peptidase and renal excretin, degrade and render GLP-1 inactive within minutes. A receptor agonist, exendin-4, with a longer biological half-life than GLP-1, has been tried. Subcutaneous injection of exendin-4 or continuous IV injection of GLP-1 warrants further research and investigation.
        
Related information
Citations formats
Frezza EE, Wachtel MS, Chiriva-Internati M (2007) The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review Digestive Diseases & Sciences52: 643-9